Altså, gitt de krav som ligger til grunn for medisinvitenskaplige studier, så tviler jeg litt på at de behandler dataen såpass lemfeldig at administrativt/uautorisert personell har tilgang på det. Det ville rett og slett vært fryktelig svekkende for studiens kvalitet - og det vil man på ingen måte være tjent med.

Coronavirus Vaccine Tracker

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html?smid=wa-share

Det er sikkert lurt å bruke begge deler , men først må BGBIO få «ræven i gir»( Bergen utrykk) ...

Det somles på laboratoriene og i administrasjonen synes jeg - alt for mange innsidere vet muligens resultatene på Accord testene og hamstrer kanskje aksjer i BGBIO på megler konti som går «under radaren» til Finanstilsynet...

Hadde vert kjekt med noen svar snart. Hvis de er positive kan det bli riktig så hyggelig. Er selvsagt ikke bare å slutte med vaksiner, kan man kjøre begge deler?

NRK:

Studier: Vaksinen kan beskytte dårligere mot nye koronavarianter

Koronamutasjoner fra Sør-Afrika og Brasil har endret seg så mye at vaksinene kanskje ikke virker, antyder nye studier. De nye koronavariantene både smitter lettere og kan smitte på nytt. Det bekymrer Folkehelseinstituttet.

Les hele artikkelen her :


https://www.nrk.no/norge/koronavaksinen-kan-gi-darlig-beskyttelse-mot-nye-mutasjoner-fra-brasil-og-sor-afrika-1.15339681

Gi oss Bemcentinib!


VAKSINEPRODUKSJONEN TIL ASTRAZENECA FORSINKET
Vaksineprodusenten AstraZeneca har varslet EU-kommisjonen at de ikke kan levere vaksinedosene de har lovet EU-landene like raskt som avtalt, melder den tyske avisen Bild.

Ifølge avisen skal selskapet bare være i stand til å levere et betydelig lavere antall doser enn de avtalte 56,5 dosene til Tyskland i 2021. Det betyr at hele leveransen er forsinket.




https://m.bild.de/politik/inland/politik-inland/naechstes-impf-debakel-kuendigt-sich-an-lieferprobleme-bei-astrazeneca-75019752.bildMobile.html#%23%23wt_ref=https%3A%2F%2Fdirekte.vg.no&wt_t=1611334003590

Vaksiner blir mindre og mindre effektive mot nye COVID-19 mutasjoner..Vaksine optimistene begynner å tvile .
Nå trenger verden Bemcentinib fra BerGenBio på «Blå Resept».

Fauci: New data shows Covid vaccines may be less effective against some new strains

Sent from the CNBC app. Available on the App Store

Dr. Fauci says new data shows Covid vaccines appear to be less effective against some new strains
PUBLISHED THU, JAN 21 20214:31 PM ESTUPDATED THU, JAN 21 20216:46 PM EST
Noah Higgins-Dunn
@HIGGINSDUNN
Early data shows that the Covid-19 vaccines on the market may not be as effective in guarding against more contagious strains of the coronavirus, Dr. Anthony Fauci said Thursday.
Even if the drugs are less effective, they will still likely provide enough protection to make the vaccines worth getting, he said.
A dip in the vaccines’ effectiveness would be “all the more reason why we should be vaccinating as many people as you possibly can,” Fauci added.

New data shows that the Covid-19 vaccines currently on the market may not be as effective in guarding against new, more contagious strains of the coronavirus, White House health advisor Dr. Anthony Fauci said on Thursday.

A handful of new strains of the coronavirus have emerged overseas that have given scientists some cause for concern. Some variants that have been identified in the United Kingdom, South Africa and Brazil appear to be more transmissible than previous strains but not necessarily more deadly.

While it’s no surprise the virus is mutating, researchers are quickly trying to determine what the changes might mean for recently developed lifesaving vaccines and therapeutics against the disease.

Some early findings that were published in the preprint server bioRxiv, which have yet to be peer reviewed, indicate that the variant identified in South Africa, known as 501Y.V2, can evade the antibodies provided by some coronavirus treatments and may reduce the efficacy of the current line of available vaccines.

“Furthermore, 501Y.V2 shows substantial or complete escape from neutralising antibodies in COVID-19 convalescent plasma,” researchers with South Africa’s National Institute for Communicable Diseases wrote. Their conclusions, they said, “highlight the prospect of reinfection ... and may foreshadow reduced efficacy of current spike-based vaccines.”

Even if the drugs are less effective, they will still likely provide enough protection to make the vaccines worth getting, Fauci said during a White House press briefing.

Both vaccines from Pfizer and Moderna have proven to be highly effective, creating a “cushion effect” that would allow for some dip in their effectiveness.

“We’re following very carefully the one in South Africa, which is a little bit more concerning, but nonetheless not something that we don’t think we can handle,” Fauci said.

A dip in the vaccines’ effectiveness would be “all the more reason why we should be vaccinating as many people as you possibly can.” Mutations occur when the virus spreads and replicates itself, which can be suppressed if enough people are inoculated against the disease to build so-called herd immunity, he explained.

“Bottom line: We’re paying very close attention to it. There are alternative plans if we ever have to modify the vaccine. That’s not something that is a very onerous thing, we can do that given the platforms we have,” Fauci said.

Dr. Rochelle Walensky, the new director for the Centers for Disease Control and Prevention, said on Tuesday that while she believes the vaccines will work against the mutated variants, they may not end up as effective as they were in clinical trials.

“I’m really optimistic about how these variants are going to go,” Walensky said in an interview with the JAMA Network. “I could be wrong. It could be that we’ll find variants and variants may emerge ... where the vaccine is less potent, but I’m still currently optimistic.”

So far, the United States has not detected any cases of Covid-19 with the strain identified in South Africa, Fauci said, though he added that the level of surveillance for the strains “is not at the level that we would have liked.”

Another study printed in bioRxiv by Pfizer and BioNTech’s scientists found that their Covid-19 vaccine was likely to be just as effective against the mutated, infectious strain that was discovered in the U.K. The U.S. has identified at least 144 cases with that variant so far, according to recent data from the CDC.

Authors of the study warned that the rapid spread of Covid variants worldwide required “continuous monitoring of the significance of changes for maintained protection by currently authorized vaccines.”

— Reuters and CNBC’s Sam Meredith contributed to this report.

Yes I am (100%) ...

og når bomben springer vil vi alle ønske vi havde lastet mere op pånær dem med 100% af PF i BGBIO

kom så BGBIO ! kom så BGBIO ! kom så BGBIO ! kom så BGBIO....

focuss - din tålmodighed er nød til at række en uge i første omgang hen til WCLC konferensen. :-)
jeg tror også mikrofly35 er lige hurtig nok. jeg læser din besked som at de er vældig meget utålmodig på om der ikke snart kommer resultater, hvilket tyder på du ligger tungt lastet. med de positive indikationer der findes er jeg enig i at det er utroligt at man ikke får skabt flere resultater hurtigt. hvorfor kan man ikke lave intensiv test i Norge..? I må da være interesseret i at redde verden...? kom nu igang for pokker - råb op sykehuse og politikere så vi kan få de grimme vacciner udkonkurrert :-)

Må være feberfantasier. Mine Magseis aksjer har det helt utmerket, det har forresten de fleste av aksjene i min portefølje..

It's time :)

Vi tok rotta på deg i mseis og skal gjøre det samme her, vi hadde nok muskler til å knekke deg der :)

Satser vi så satser vi og vi satser ikke uten at vi vet vi har ressurser nok :)

Har du sluppet ut nesten alt sliter du. Time will tell.

Jeg har da ikke solgt. Det er en del av din dårlige analyse. Hadde jeg gjort det hadde jeg brydd meg katta om denne ledelsen. Ser ikke bort fra at jeg har flere aksjer enn deg.

Vi får se, du solgte til feil gruppe, og vi er sultne.

Mohn er en god sikkerhet mot at selskapet blir kjøpt opp for røverpris.

Mohn og Co virker å være optimister da. Men til forskjell fra deg, så har de gjerne ikke peiling på hva de driver med.

Dårlig analyse som vanlig.

Alltid like morsomt å se når du og 2 til har satt short posisjonen deres, da er dere her inne og syter,
Det har ikke godt så godt i det siste, har det vel :)
Dere får en liten overraskelse i morgen.

Her mangler det meste. Vi har ikke engang sett en plan eller målsetting for når man kan forvente å ha noen resultater og vise til. Virker jo som verden er totalt uinteressert i hva BGBIO driver med også. Er det fordi at Bemcentinib er en av hundrevis med alternativer? Da betydde det ikke så mye om Bemcentinib var først av alternativene i Accord studien eller om det rett og slett ikke var andre kandidater.

Synes det er for jevlig at de skal ta seg så fryktelig god tid med å finne ut om Bemcentinib er nyttig eller ikke. Verden renner jo over av pasienter men det synes som det tar lengre tid å finne ut om Bemcentinb har effekt enn å utvikle en vaksine, som det sies at normalt tar 5-10 år å gjøre. Har ikke de som driver med disse studiene oppdaget at det er emergency og det kan søkes om EUA?

Ny variant: - Betydelig risiko for resmitte:
Den muterte coronavirusvarianten fra Sør-Afrika øker betraktelig risikoen for å bli coronasmittet på nytt, viser ny forskning.
Funnene fører til bekymring for at vaksinene kan være mindre effektive mot mutasjonen, viser tidlige resultater fra studien lagt fram onsdag.

Andre studier har vist at vaksinene trolig vil virke effektivt mot den muterte varianten fra Storbritannia.

Forskere i Sør-Afrika har testet den muterte varianten – 501Y.V2 – mot blodet til friskmeldte coronasmittede personer. De oppdaget at varianten er motstandsdyktig til antistoffene fra sykdommen.

- Dette indikerer at nye varianter som 501Y.V2 utgjør en betydelig risiko for å bli smittet på nytt, konkluderte forskerne.

(NTB

Vaksinene er designet for å virke mot mange mutasjoner. Om de avviker for mye må det lages nye vaksiner på samme "platform" som inkluderer mutasjoner som har kommet til i etterkant. Om mutasjoner skjer på helt andre steder, eller er svært annerledes kan det være at det må lages helt andre vaksiner eller medisiner. Dess lengre bort fra normalen du beveger deg, dess mindre sannsynlig er det at det skjer. Men når det gjelder covid, så er det så mange som er smittet, at det får et enormt antall sjanser til å mutere. I tillegg kan større avvik i mutasjonene oppstå når det smitter fra mennesker til dyr, og tilbake til mennesker. Det kan tenkes at når smitte er utbredt hos farmere, eller for eksempel hos urfolk i Brasil, øker risikoen for mer ekstreme mutasjoner. Vi har allerede eksempel fra Danmark og Brasil. Brasil varianten(e) er det jo fortsatt noen spørsmålstegn rundt, i forhold til om vaksinene er like effektive mot dem.
(Ref Sinovac vaksinen som kanskje er mindre effektiv i Brasil enn den var i Indonesia og Tyrkia).

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30624-7#

La oss si at det etter hvert er 9 ulike varianter som dagens vaksiner ikke virker mot.
Kan 10 vaksiner pakkes sammen i en og samme sprøyte?
Eller blir det kaos? Må folk ta ulike sprøyter for de forskjellige variantene?
Og at de må tas f.eks en gang i året for å sikre at immunforsvaret er godt nok.

Mer om california-varianten:
https://www.nytimes.com/2021/01/19/health/coronavirus-variant-california.html#click=https://t.co/wC87HEMC2z

Nå har det kommet flere indikasjoner på at amerikanske covid varianter inneholder egne, skumlere mutasjoner i S-proteinet, blant annet L452R, og at noen av variantene har kombinasjoner av mutasjoner som antagelig gjør viruset mer smittsomt enn D614 og G614 variantene som var dominerende i Europa inntil litt før juletider.

Det er fortsatt usikkert om vaksinene er effektiv mot L452R varianten, evt om vaksinene er mindre effektiv når viruset inneholder L452R mutasjonen og visse andre mutasjoner i tillegg.

Med alle disse nye mutasjonene som dukker opp, så er det antagelig kun et tidsspørsmål før det kommer mutasjoner som vaksinene ikke virker mot.

Blokkert Bruker. (innlegget er skjult).

Hva gjør Godfrey med dette?

oi oi.
https://www.abcnyheter.no/nyheter/verden/2021/01/19/195734066/kina-opplever-sitt-storste-coronautbrudd-siden-mars

VERDENS SENSASJON fra BerGenBio ✨✨✨👍

Fra SEB presentasjon (s.5) i går :
https://www.bergenbio.com/wp-content/uploads/2021/01/BerGenBio_SEB_Jan21.pdf


Legg merke til

Fibrosis
• Renal
• NASH
• IPF
• MF
•COPD (KOLS ) ✨✨✨👍

er en alvorlig lunge sykdom Bemcentinib også kan helbrede.

COPD / KOLS er en sykdom / infeksjon i lungene som reduserer oksygenopptak på lik linje med fibrose under /,etter COVID-19. For meg er det åpenbart at når Bemcentinib gir kun milde symptomer på COVID-19 så vil også pasienter med COPD/KOLS få betydelig bedre lungekapasitet med Bemcentinib.

Antall pasienter som har COPD/KOLS i verden er meget høyt - 3 millioner mennesker dør hvert år av COPD/KOLS .

I 2020 døde 1.810.000 mennesker av COVID-19. https://ourworldindata.org/covid-deaths

DETTE ER MEGET LOVENDE FOR BGBIO....

https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally.

👏👏👏

Henger meg på her, som så mange ganger før, skjønner lite av de som selger nå, teknisk er det strake veien til 50.
Fundamentalt kan den gå rett til 100

VERDENS SENSASJON fra BerGenBio ✨✨✨👍

Fra SEB presentasjon (s.5) i går :
https://www.bergenbio.com/wp-content/uploads/2021/01/BerGenBio_SEB_Jan21.pdf


Legg merke til

Fibrosis
• Renal
• NASH
• IPF
• MF
•COPD (KOLS ) ✨✨✨👍

er en alvorlig lunge sykdom Bemcentinib også kan helbrede.

COPD / KOLS er en sykdom / infeksjon i lungene som reduserer oksygenopptak på lik linje med fibrose under /,etter COVID-19. For meg er det åpenbart at når Bemcentinib gir kun milde symptomer på COVID-19 så vil også pasienter med COPD/KOLS få betydelig bedre lungekapasitet med Bemcentinib.

Antall pasienter som har COPD/KOLS i verden er meget høyt - 3 millioner mennesker dør hvert år av COPD/KOLS .

I 2020 døde 1.810.000 mennesker av COVID-19. https://ourworldindata.org/covid-deaths

DETTE ER MEGET LOVENDE FOR BGBIO....

https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally.

Gi oss en pille Bemcentinib om Dagen fremfor 7 uker i helvetes advents kalender:

Våren 2020 En sann historie fra virkeligheten...

Paul Garner: For 7 weeks I have been through a roller coaster of ill health, extreme emotions, and utter exhaustion
May 5, 2020
Paul Garner, professor of infectious diseases at Liverpool School of Tropical Medicine, discusses his experience of having covid-19

In mid March I developed covid-19. For almost seven weeks I have been through a roller coaster of ill health, extreme emotions, and utter exhaustion. Although not hospitalised, it has been frightening and long. The illness ebbs and flows, but never goes away. Health professionals, employers, partners, and people with the disease need to know that this illness can last for weeks, and the long tail is not some “post-viral fatigue syndrome”—it is the disease. People who have a more protracted illness need help to understand and cope with the constantly shifting, bizarre symptoms, and their unpredictable course.

Early March seems so far away. I watched Boris introduce social distancing and then shake hands on national television; I talked with epidemiological colleagues about the established effects of austerity increasing mortality in the poor, and how lockdown would worsen this; I advised my 97 year old father to isolate. I said to myself that years of running and military fitness would protect me from harm. I discounted a runny nose, carefully checked my temperature every day, and examined the CDC/WHO comparison table and decided I did not have covid-19. Then one afternoon I started feeling strange: I happened to be on a zoom meeting with David Nabarro who said anyone who felt unwell should isolate instantly, on the spot. I went home early, and then the journey began.

In the first days at home I wasn’t sure I had covid-19. Then I damaged my hands with bleach. It had no smell, I assumed it was old and inactive—but it was just I could not smell the chlorine. The heaviness and malaise became worse, I had a tightness in the chest, and realised it could be nothing else. I was mortified that I might have infected the staff I had worked with for over 20 years. I imagined their vulnerable relatives dying and never forgiving myself. My mind was a mess. My condition deteriorated. One afternoon I suddenly developed a tachycardia, tightness in the chest, and felt so unwell I thought I was dying. My mind became foggy. I tried to google fulminating myocarditis, but couldn’t navigate the screen properly. There was nothing to do. I thought, if this is it so be it.

A few hours later I woke up, alive, and the tightness replaced by extreme fatigue. Every day, day after day. Sometimes I felt better and became optimistic; after all, the paralytic state had not recurred; but then the next day I felt as though someone had hit me around the head with a cricket bat. Staff at work criticised me for not being clear “make up your mind! Are you getting better or not?” I guess they were frightened too, but I really could not understand what was happening.

The illness went on and on. The symptoms changed, it was like an advent calendar, every day there was a surprise, something new. A muggy head; acutely painful calf; upset stomach; tinnitus; pins and needles; aching all over; breathlessness; dizziness; arthritis in my hands; weird sensation in the skin with synthetic materials. Gentle exercise or walking made me worse—I would feel absolutely dreadful the next day. I started talking to others. I found a marathon runner who had tried 8 km in her second week, which caused her to collapse with rigors and sleep for 24 hours. I spoke to others experiencing weird symptoms, which were often discounted by those around them as anxiety, making them doubt themselves.

The internet described recovery times of about two weeks for people that had not been hospitalised. I had not had severe disease, yet here I was after four weeks still unwell. My doctor neighbour and GP were concerned. I consulted with friends who were consultants in infectious diseases by email and they wondered if I had more lung involvement than I had estimated. My tenant had friends who were still ill at four weeks and this helped a lot.

The least helpful comments were from people who explained to me that I had post viral fatigue. I knew this was wrong. There was a pattern in that period from two weeks to six weeks: feeling absolutely dreadful during the day; sleep heavily, waking with the bed drenched in sweat; getting up with a blinding headache, receding during the day, turning me into a battered ragdoll in the evening.

I joined a Facebook page (Covid-19 Support Group (have it/had it)) full of people with these stories, some from the UK, some from the US. People suffering from the disease, but not believing their symptoms were real; their families thinking the symptoms were anxiety; employers telling people they had to return to work, as the two weeks for the illness was up. And the posts reflect this “I thought I was going crazy for not getting better in their time frame”; “the doctor said there is zero reason to believe it lasts this long”. And too, people report that their families do not believe their ever changing symptoms, that it is psychological, it is the stress.

Over the weeks, I have been touched by the people that have quietly stepped in to help me cope, appropriate, unobtrusive, timely. Family, friends, colleagues, and neighbours. Our local yoga studio’s motto is “a community building strength in mind, body and heart.” This love and support of gives us a direction for our future. And today the disease has lifted. For the first time, I do not feel awful.

The aim of this piece is to get this message out: for some people the illness goes on for a few weeks. Symptoms come and go, are strange and frightening. The exhaustion is severe, real, and part of the illness. And we all need support and love from the community around us.

Paul Garner is Professor at the Liverpool School of Tropical Medicine. He is Director of the Centre for Evidence Synthesis in Global Health and Co-ordinating Editor of the Cochrane Infectious Diseases Group.

Twitter: @PaulGarnerWoof

Er vaksinen så uproblematisk som den fremstår?
https://legemiddelverket.no/english/covid-19-and-medicines/vaccines-against-covid-19/reported-suspected-adverse-reactions-of-covid-19-vaccines
https://nypost.com/2021/01/15/23-die-in-norway-after-receiving-pfizer-covid-19-vaccine/

Mange gode artikler 👌
www.Nature.com på søk : Bemcentinib

https://www.nature.com/search?q=Bemcentinib+

Eks:


https://www.nature.com/articles/s41392-020-00361-x


NEWS IN BRIEF 11 MAY 2020
COVID umbrella trials multiply
https://www.nature.com/articles/d41573-020-00089-x

Biobull, her er masse god relevant info i favør AXL , og veldig relevant til Bergenbio, liker spesielt at artikkelen/studie er ferskvare,,  8 January 2021 

Gledelig fra www.Nature.com om AXL :

https://www.nature.com/search?q=%20AXL%20inhibitor&order=relevance

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells
...tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the... ...we found that overexpression of AXL in HEK293T cells promotes SARS... ...of ACE2, while knocking out AXL significantly reduces SARS-CoV-2... ...cells. Soluble human recombinant AXL blocks SARS-CoV-2... ...of AXL...
Shuai Wang, Zongyang Qiu[…]Xu Li
Cell Research , 1–15

The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge. The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry. Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, especially in the respiratory tract. Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist. In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S. Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells. Soluble human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL. The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients. Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clinical intervention strategies.

https://www.nature.com/articles/s41422-020-00460-y.pdf

Litt lesestoff jeg fant interessant og oppsummerende, dersom noen skulle ønske å sette seg enda mer inn i caset. Vil også påpeke at i november anså Edison group, et "investor research" byrå, at aksjekursen burde ligget på risikojusterte 60 kroner. Det vil si at kursen, per dags dato, burde sett over* en 60% oppside. I tillegg; i dag er risikoen gjerne enda lavere enn det den var i november, sett i kjølvannet av de nyeste børsmeldingene.

Artikkel:
https://www.edisongroup.com/publication/bemcentinib-leading-the-axl-charge/28247/

NB: Artikkelen er fra 17. november 2020.

Edit: WCLC 2020, 29. januar 2021, abstrakt: https://library.iaslc.org/conference-program?product_id=20&date=2021-01-29 - veldig lovende.